DEADLINE NEXT TUESDAY: Shareholders who have suffered substantial losses have the option of pursuing the Ocugen, Inc. class action lawsuit.

SAN DIEGO, August 13, 2021 / PRNewswire / – Robbins Geller Rudman & Dowd LLP announces that the Ocugen, Inc. The class action lawsuit accuses Ocugen, Inc. (NASDAQ: OCGN) and some of its senior executives of violations of the Securities Exchange Act of 1934 and seeks to represent buyers of Ocugen securities between February 2, 2021 and June 10, 2021, inclusive (the “Recourse Period”). the Ocugen class action (Nicanor v. Ocugen, Inc., n ° 21-cv-02725) was initiated on June 17, 2021 and is on hold in the Eastern District of Pennsylvania. A similar trial, Diaz v. Ocugen, Inc., No. 21-cv-03182, is also pending in the eastern district of Pennsylvania.

If you have suffered substantial losses and wish to be the primary claimant of the Ocugen class action lawsuit, please provide your information by clicking here. You can also contact Robbins Geller’s lawyer JC Sanchez by calling 800 / 449-4900 or emailing [email protected] The principal applicant’s requests for the Ocugen the class action must be filed with the court at the latest August 17, 2021.

CASE ALLEGATIONS: The Ocugen The class action alleges that, throughout the class action period, the defendants made false and misleading statements and failed to disclose that: (i) information that Ocugen submitted to the State Food and Drug Administration -United (“FDA”) were insufficient to justify an Emergency Use Authorization (“EUA”); (ii) Ocugen would not file an EUA with the FDA; and (iii) as a result, Ocugen’s financial statements, as well as the statements of the defendants regarding Ocugen’s business, operations and prospects were false and misleading and / or lacked reasonable basis.

On June 10, 2021, Ocugen issued a press release announcing that it would pursue a Biologics License Application (“BLA”) with the FDA instead of the previously announced EUA. In doing so, Ocugen revealed that “[t]FDA provided comments to Ocugen regarding the main dossier the company had previously submitted and recommended that Ocugen pursue a BLA submission instead of an EUA application for its vaccine candidate and requested additional information and data . Ocugen is in discussions with the FDA to understand the additional information required to support a BLA submission. The Company anticipates that data from an additional clinical trial will be required to support the submission.

THE MAIN COMPLAINANT PROCESS: The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Ocugen securities during the Recourse Period to seek appointment as principal plaintiff in the Ocugen class action lawsuit. A principal plaintiff is generally the plaintiff with the greatest financial interest in the remedy sought by the putative class which is also typical and adequate of the putative class. A lead applicant acts on behalf of all other class members by ordering Ocugen class action lawsuit. The lead plaintiff can choose a law firm of their choice to litigate the case. Ocugen class action lawsuit. The ability of an investor to participate in any potential future recovery of the Ocugen the class action does not depend on the function of principal plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 offices across the country, Robbins Geller Rudman & Dowd LLP is the largest US law firm representing investors in securities class actions. Robbins Geller lawyers have secured many of the biggest shareholder recoveries in history, including the largest securities class action recovery ever – $ 7.2 billion – in In re Enron Corp. Dry. Litigation. 2020 ISS Securities Class Action Services Top 50 report ranked Robbins Geller # 1 for recovery $ 1.6 billion for investors last year, more than double the amount recovered by any other company from securities claimants. Please visit for more information.

Lawyer advertising.
Past results do not guarantee future results.
Services can be performed by lawyers in one of our offices.


Robbins Geller Rudman & Dowd LLP

655 W. Broadway, San Diego, CA 92101

JC Sanchez, 800-449-4900

[email protected]


View original content: – trial-ocgn-301354743.html

SOURCE Robbins Geller Rudman & Dowd LLP

Comments are closed.